The Medical Letter on Drugs and Therapeutics
In Brief: An Aromatase Inhibitor Is Reported to Prevent Postmenopausal Breast Cancer
Download PDF:   US English
Med Lett Drugs Ther. 2011 Jun 13;53(1366):48
 Select a term to see related articles  Aromasin   Aromatase inhibitors   breast cancer   Exemestane 

A randomized, placebo-controlled, double-blind trial of exemestane (Aromasin, and others) in postmenopausal women considered at increased risk for breast cancer found that the aromatase inhibitor, over a median follow-up of 35 months, significantly decreased the annual incidence of invasive breast cancer from 0.55% to 0.19% (PE Goss et al. N Engl J Med, epub June 4, 2011).

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article